LAST MINUTE NEWS: The US Food and Drug Administration (FDA), Pfizer-Biontech’s coronavirus vaccine. Said his data ‘met the prescribed success criteria’ for emergency use authorization.
The FDA added that the vaccine does not raise any safety concerns that would prevent it from being granted emergency use.
In a statement made by the US Food and Drug Administration (FDA), Data on Pfizer-Biontech corona virus vaccine. Complies with the rules on emergency use authorization. And explained that the vaccine raises hopes for people aged 16 and over.
In the report published by the FDA, the corona virus vaccine developed by the German Pfizer and Biontech. The FDA stated that it is very effective in preventing Covid-19.
The FDA also underlined that the vaccine has no safety concerns that would prevent it from being issued for emergency use.
While the FDA states that people who have had corona virus before can be vaccinated, Pfizer-Biontech coronavirus vaccine is, stated that there is not enough data on whether it can be used in pregnant women and individuals with weakened immunity.
Preliminary data of the Pfizer-Biontech vaccine can provide serious protection against deaths from Covid-19. However, underlined that a general conclusion cannot be drawn due to limited data.
While the FDA says the Pfizer-Biontech Covid-19 vaccine provides some protection after one dose. The FDA stated that the effectiveness of the vaccine was around 52 percent after the first dose.
The FDA added that the Pfizer-Biontech corona virus vaccine achieved 94 percent success in the 55 and older age group. The US Food and Drug Administration is expected to give approval for emergency use of the Pfizer-Biontech corona virus vaccine on Thursday, December 10.